Abstract 108P
Background
The human epidermal growth factor receptor 2 (HER2/neu) play a predictive and prognostic role in colorectal cancer (CRC). Accurate evaluating of HER2 overexpression is required for selection and determination of eligible patients for HER2-directed therapy or primary resistance and poor response to anti-EGFR therapy. However, there is no currently established best practice for HER2 testing and interpretation in CRC. The purpose of this study was to validate and evaluate the performance of AmoyDx® HANDLE Classic NGS Panel (CP40) in assessing HER2 status by comparing it with HER2 IHC (4B5)/FISH analysis.
Methods
The CP40 is based on Halo-shape ANnealing and Defer-Ligation Enrichment (HANDLE) system technology, which allows high sensitivity in 40 key solid tumour genes qualitative detection and microsatellite instability (MSI) status assessment utilizing DNA and RNA. Performance of the CP40 was compared against the HER2 IHC/FISH assay according to the HERACLES scoring criteria using 805 CRC samples. Only samples with a ratio ERBB2:CEN17 ≥ 2 or staining equivocal (2+) or positive (3+) in at least 50% of cells were determined as HER2 IHC/FISH positive.
Results
CP40 and IHC/FISH assays were highly concordant in their assessment of HER2 status in CRCs (99.50%, 801/805, kappa = 0.892). Three conflicting results were negative in CP40 but were scored 2+ in 50-70% of the cells and identified as positive by IHC/FISH. One CRC scored as 3+ in 40% cells was determined to be negative by both CP40 and IHC/FISH. And all MSI CRCs were evaluated as HER2 negative by both CP40 and IHC. Table: 108P
Comparison of HER2 status determined from CP40 and IHC/FISH assays
ERBB2 NGS-based CNV testing | ||||
True | False | Total | ||
HER2 IHC/FISH assay | Positive | 17 | 3 | 20 |
Negative | 1 | 784 | 785 | |
Total | 18 | 787 | 805 | |
Kappa= | 0.892 | |||
Overall coincidence rate = | 99.50% |
Conclusions
CRC-specific HER2 testing protocols and HER2 scoring criteria still needs to be optimised in a more refined and defined manner. HANDLE-based CP40, which combines DNA and RNA in NGS testing, is a potent tool for sensitive and reliable detection of HER2 status in clinical diagnostics.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract